Definium To Highlight Phase 3 Data And New Research On Anxiety, Depression At Psych Congress
Benzinga Newsdesk 1 month ago
News
Emerge Phase 3 study podium poster to be featured in "Latest Discoveries & Emerging Trends in MDD" sessionNew epidemiological research on risks associated with anxiety and depression plus five posters across
Emerge Phase 3 study podium poster to be featured in "Latest Discoveries & Emerging Trends in MDD" session
New epidemiological research on risks associated with anxiety and depression plus five posters across clinical program
Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced six poster presentations at the Psych Congress taking place September 15 through 19 in New Orleans, LA.